PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Recruiting · Phase 2 · NCT06617481
Conditions: Prostate Cancer (Post Prostatectomy)
At a glance
- Research payments reported, 2025
- $238,093
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- AdventHealth (with Blue Earth Diagnostics)
- Tested
- 18F-rhPSMA-7.3 (Posluma) (drug)
- Dates
- Started 2024-09-20; completion 2027-10-10
- Results posted
- Not yet
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
From ClinicalTrials.gov, last updated 2024-10-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $238,093 in research payments for this study in 2025 (47 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.